Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Last Updated: Monday, November 21, 2022
This study examined CAR T-cell therapy for systemic lupus erythematosus (SLE). Although an extremely small population, drug-free remission was maintained for up to 8 months post-CAR T-cell infusion. In addition, CAR T-cell infusion was well tolerated, with only mild cytokine release syndrome seen as an adverse event.
Advertisement
News & Literature Highlights
